"Interferon-beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity.
| Descriptor ID |
D016899
|
| MeSH Number(s) |
D12.644.276.374.440.890.275 D12.776.467.374.440.890.275 D23.529.374.440.890.275
|
| Concept/Terms |
Interferon-beta- Interferon-beta
- Interferon beta
- Interferon, Fibroblast
- Fibroblast Interferon
- Interferon, beta
- beta Interferon
- beta-Interferon
beta-1 Interferon- beta-1 Interferon
- beta 1 Interferon
- Interferon-beta1
- Interferon beta1
- Interferon, beta-1
- Interferon, beta 1
|
Below are MeSH descriptors whose meaning is more general than "Interferon-beta".
Below are MeSH descriptors whose meaning is more specific than "Interferon-beta".
This graph shows the total number of publications written about "Interferon-beta" by people in this website by year, and whether "Interferon-beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 5 | 0 | 5 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 3 | 1 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 3 | 5 |
| 2007 | 3 | 0 | 3 |
| 2008 | 4 | 1 | 5 |
| 2009 | 4 | 1 | 5 |
| 2010 | 5 | 2 | 7 |
| 2011 | 4 | 4 | 8 |
| 2012 | 5 | 1 | 6 |
| 2013 | 3 | 1 | 4 |
| 2014 | 4 | 2 | 6 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-beta" by people in Profiles.
-
Alternative Splicing of RNA Is Excessive in Multiple Sclerosis and Not Linked to Gene Expression Levels: Dysregulation Is Corrected by IFN-ß. J Interferon Cytokine Res. 2024 08; 44(8):355-371.
-
Increased Type I interferon signaling and brain endothelial barrier dysfunction in an experimental model of Alzheimer's disease. Sci Rep. 2022 10 01; 12(1):16488.
-
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
-
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler. 2021 12; 27(14):2219-2231.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019 Nov; 49:269-283.
-
Zika Virus NS3 Mimics a Cellular 14-3-3-Binding Motif to Antagonize RIG-I- and MDA5-Mediated Innate Immunity. Cell Host Microbe. 2019 10 09; 26(4):493-503.e6.
-
Vitamin D enhances responses to interferon-ß in MS. Neurol Neuroimmunol Neuroinflamm. 2019 11; 6(6):e622.
-
Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes. Nat Microbiol. 2018 10; 3(10):1099-1108.
-
PUM1 is a biphasic negative regulator of innate immunity genes by suppressing LGP2. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6902-E6911.